Today
Top Picks
News
Recent Research
Quant Portfolios
Information Technology
Consumer Discretionary
Industrials
Financials
Health Care
Communication Services
Energy
Real Estate
Materials
Premium HEALTH CARE
materialicons-round-2403
CVS Swaps CEOs in Hopes of Riding Corporate America’s Hottest Trend
More than a month ago
Premium PHARMA
materialicons-round-2403
Pfizer’s $1B Pill Problem
More than a month ago
Premium Price Target: $700 (19% upside)
materialicons-round-2403
Eli Lilly: The Biggest Threat to Ozempic
More than 1 year ago
Premium Price Target: $10 (25% upside)
materialicons-round-2403
MorphoSys: A New Biotech Play
More than 1 year ago
Premium Price Target: $44 (30% upside)
materialicons-round-2403
Intellia: Is Gene Editing The Future of Medicine?
More than 1 year ago
Premium
materialicons-round-2403
Eli Lilly's Chronic Pincer Move
More than 1 year ago
Premium Price Target: $554 (18% upside)
materialicons-round-2403
Elevance Health: Profiting from the Wealthiest Generation
More than 1 year ago
Premium
materialicons-round-2403
Shockwave: The Sleeper in Biotech
More than 1 year ago
Premium
materialicons-round-2403
Evotec: The Best AI Healthcare Play
More than 1 year ago
Premium Price Target: $88 (19% upside)
materialicons-round-2403
AstraZeneca's AI Cancer Missiles
More than 1 year ago
Premium Price Target: $483 (15% upside)
materialicons-round-2403
How Eli Lilly is Abolishing Obesity
More than 1 year ago
Premium Price Target: $140 (21% upside)
materialicons-round-2403
Merck's Secret Weapon Against Cancer
More than 1 year ago
Premium Price Target: $340 (16% upside)
materialicons-round-2403
Intuitive Surgical: The Right Growth at the Right Time
More than 1 year ago
Premium
materialicons-round-2403
Illumina: A Famous Activist Coming Aboard
More than 1 year ago
Premium
materialicons-round-2403
Zoetis: Diversified and Poised for Growth
More than 1 year ago
Premium
materialicons-round-2403
Merck: Getting Closer To Solving Cancer
2 years ago
Premium
materialicons-round-2403
Intuitive Surgical: A Strong Return to Medical Normal
2 years ago
Premium
materialicons-round-2403
Eli Lilly: The Biggest Healthcare Advancement In A Decade
2 years ago
Premium
materialicons-round-2403
Illumina is About to Corner the DNA Market
2 years ago
Premium
materialicons-round-2403
Biogen: A Crossroads to Complete our Pharma Trifecta
2 years ago
Premium Price Target: $388 (28% upside)
materialicons-round-2403
Eli Lilly: A Solid Discount Before the Big Show
2 years ago
Premium Price Target: $689 (21% upside)
materialicons-round-2403
Thermo Fischer Scientific: Pivoting to Growth
2 years ago
Premium Price Target: $342 (20% upside)
materialicons-round-2403
Eli Lilly: Defeating America's Biggest Health Crisis
2 years ago
Premium Price Target: $105 (24% upside)
materialicons-round-2403
Merck: Medical Breakthrough After Breakthrough
3 years ago